Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVSX6O)

• Drug Name: Tebipenem Drug Info
• Synonyms: Tebipenem [INN]

Indication

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Phase 3	[1]
Nicotine dependence	6C4A.2	Phase 2	[2]
Obesity	5B81	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 9800194
  CAS Number: CAS 161715-21-5
  TTD Drug ID: DMVSX6O

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[3]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[5]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[6]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[7]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[8]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[9]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[10]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[11]
V-24343	DMJSX9N	Type-2 diabetes	5A11	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT03788967) Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO). U.S. National Institutes of Health.
• [2] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [3] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [4] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [5] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [6] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [7] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [8] Company report (Gwpharm)
• [9] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [10] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [11] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [12] Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65.